Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses

Journal of Virology

Volumn 86, Issue 21, 2012, Pages 11754-11762

  Kim, Yunjeong ^a   Lovell, Scott ^b   Tiew, Kok Chuan ^c   Mandadapu, Sivakoteswara Rao ^c   Alliston, Kevin ^c   Battaile, Kevin ^d   Groutas, William ^c   Chang, Kyeong Ok ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c WICHITA STATE UNIVERSITY   (United States)

^d IMCA CAT Hauptman Woodward Medical Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA KETOAMIDE; ANTIVIRUS AGENT; DIPEPTIDYL ALDEHYDE; DIPEPTIDYL BISULFITE ADDUCT SALT; GC 373; GC 375; GC 376; PROTEINASE; RUPINTRIVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CONTROLLED STUDY; CORONAVIRUS; CRYSTAL STRUCTURE; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NOROVIRUS; NUCLEOPHILICITY; PICORNAVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CORONAVIRUS; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; HUMANS; INHIBITORY CONCENTRATION 50; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; NOROVIRUS; PICORNAVIRIDAE; PROTEASE INHIBITORS; PROTEIN CONFORMATION; VIRAL PROTEINS;

CALICIVIRIDAE; NORWALK VIRUS; PICORNAVIRIDAE; POLIOVIRUS; RNA VIRUSES; TRANSMISSIBLE GASTROENTERITIS VIRUS;

EID: 84869069227     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01348-12     Document Type: Article

References (46)

1. Adams PD, et al. 2010. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr.66:213-221.
2. Anand K, et al. 2002. Structure of coronavirus main proteinase reveals combination of a chymotrypsin fold with an extra alpha-helical domain.EMBO J. 21:3213-3224.
3. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. 2003.Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300:1763-1767.
4. Anderson J, Schiffer C, Lee SK, Swanstrom R. 2009. Viral protease inhibitors. Handb. Exp. Pharmacol. 2009:85-110.
5. Bergmann EM, Mosimann SC, Chernaia MM, Malcolm BA, James MN.1997. The refined crystal structure of the 3C gene product from hepatitis A virus: specific proteinase activity and RNA recognition. J. Virol. 71:2436-2448.
6. Binford SL, et al. 2005. Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir,a novel human rhinovirus 3C protease inhibitor. Antimicrob. Agents Chemother. 49:619-626.
7. Birtley JR, et al. 2005. Crystal structure of foot-and-mouth disease virus 3C protease. New insights into catalytic mechanism and cleavage specificity.J. Biol. Chem. 280:11520 -11527.
8. Chang KO, Sosnovtsev SV, Belliot G, King AD, Green KY. 2006. Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 353:463- 473.
9. Chang KO, Takahashi D, Prakash O, Kim Y. 2012. Characterization of proteases from norovirus genogroup I and II with the fluorescence resonance energy transfer assay. Virology 423:125-133.
10. Collaborative Computational Project Number 4. 1994. The CCP4 suite:programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr.50:760 -763.
11. De Clercq E. 2010. Antiviral therapy: quo vadis? Future Med. Chem.2:1049 -1053.
12. De Palma AM, et al. 2008. Potential use of antiviral agents in polio eradication. Emerg. Infect. Dis. 14:545-551.
13. Dragovich PS, et al. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3.Structure-activity studies of ketomethylene-containing peptidomimetics.J. Med. Chem. 42:1203-1212.
14. Dragovich PS, et al. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4.Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 42:1213-1224.
15. Emsley P, Lohkamp B, Scott WG, Cowtan K. 2010. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66:486 -501.
16. Fauquet CM, et al. 2005. Virus taxonomy: classification and nomenclature of viruses. Eighth report of the International Committee on Taxonomy of Viruses. Academic Press, San Diego, CA.
17. Grubman MJ, Baxt B. 2004. Foot-and-mouth disease. Clin. Microbiol.Rev. 17:465- 493.
18. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. 2011. Broadspectrum antiviral that interferes with de novo pyrimidine biosynthesis.Proc. Natl. Acad. Sci. U.S.A. 108:5777-5782.
19. Hussey RJ, et al. 2011. A structural study of norovirus 3C protease specificity: binding of a designed active site-directed peptide inhibitor. Biochemistry 50:240 -249.
20. Iizuka K, et al. 1988. New human renin inhibitors containing an unnatural amino acid, norstatine. J. Med. Chem. 31:701-704.
21. Jacobsen KH, Wiersma ST. 2010. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 28:6653- 6657.
22. Jaulent AM, et al. 2007. A continuous assay for foot-and-mouth disease virus 3C protease activity. Anal. Biochem. 368:130 -137.
23. Krissinel E, Henrick K. 2004. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60:2256 -2268.
24. Kuo CJ, Chi YH, Hsu JT, Liang PH. 2004. Characterization of SARSmain protease and inhibitor assay using a fluorogenic substrate. Biochem.Biophys. Res. Commun. 318:862- 867.
25. Kuo CJ, et al. 2009. Individual and common inhibitors of coronavirus and picornavirus main proteases. FEBS Lett. 583:549-555.
26. Lee CC, et al. 2009. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinc-coordinating and peptidomimetic compounds.J. Biol. Chem. 284:7646 -7655.
27. Liapakis A, Jacobson I. 2011. Telaprevir user's guide. Clin. Liver Dis.15:555-571.
28. Mandadapu SR, et al. Potent inhibition of Norwalk virus 3C protease by peptidyl α-ketoamides and α-ketoheterocycles. Bioorg. Med. Chem. 22: 4820-4826.
29. Matthews DA, et al. 1994. Structure of human rhinovirus 3C protease reveals a trypsin-like polypeptide fold, RNA-binding site, and means for cleaving precursor polyprotein. Cell 77:761-771.
30. Nakamura K, et al. 2005. A norovirus protease structure provides insights into active and substrate binding site integrity. J. Virol. 79:13685-13693.
31. Nicklin MJ, Harris KS, Pallai PV, Wimmer E. 1988. Poliovirus proteinase 3C: large-scale expression, purification, and specific cleavage activity on natural and synthetic substrates in vitro. J. Virol. 62:4586-4593.
32. Patel DV, et al. 1995. α-Hydroxy phosphinyl-based inhibitors of human renin. J. Med. Chem. 38:4557- 4569.
33. Patick AK, et al. 1999. In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease. Antimicrob. Agents Chemother.43:2444-2450.
34. Perlman S, Netland J. 2009. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 7:439-450.
35. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
36. Schechter I, Berger A. 1967. On the size of the active site in proteases. I.Papain. Biochem. Biophys. Res. Commun. 27:157-162.
37. Schultheiss T, Sommergruber W, Kusov Y, Gauss-Muller V. 1995.Cleavage specificity of purified recombinant hepatitis A virus 3C proteinase on natural substrates. J. Virol. 69:1727-1733.
38. Soares MM, King SW, Thorpe PE. 2008. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat. Med. 14:1357-1362.
39. Takahashi D, Kim Y, Chang KO, Anbanandam A, Prakash O. 2012.Backbone and side-chain (1)H, (15)N, and (13)C resonance assignments of Norwalk virus protease. Biomol. NMR Assign. 85:12570 -12577.
40. Tiew KC, et al. 2011. Design, synthesis, and evaluation of inhibitors of Norwalk virus 3C protease. Bioorg. Med. Chem. Lett. 21:5315-5319.
41. Tong L. 2002. Viral proteases. Chem. Rev. 102:4609-4626.
42. Vagin A, Teplyakov A. 2010. Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66:22-25.
43. Wolf MC, et al. 2010. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl. Acad. Sci. U.S.A. 107:3157-3162.
44. Yang H, et al. 2005. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3:e324. doi:10.1371/journal.pbio.0030324.
45. Yin J, et al. 2006. An episulfide cation (thiiranium ring) trapped in the active site of HAV 3C proteinase inactivated by peptide-based ketone inhibitors. J. Mol. Biol. 361:673-686.
46. Zeitler CE, Estes MK, Venkataram Prasad BV. 2006. X-ray crystallographic structure of the Norwalk virus protease at 1.5-A resolution. J.Virol. 80:5050-5058.